People: Concert Pharmaceuticals Inc (CNCE.OQ)
18 Oct 2019
Mr. Marc Becker is the Chief Financial Officer of Concert Pharmaceuticals Inc, effective on January 4, 2018. Mr. Becker served as the Chief Financial Officer of CRISPR Therapeutics AG, a publicly traded biotechnology company, from February 2016 to September 2017. From January 2012 to February 2016, Mr. Becker was the Chief Financial Officer of rEVO Biologics, Inc., a biotechnology company. Prior to rEVO Biologics, Mr. Becker held roles of increasing responsibility at Genzyme Corporation, a biotechnology company subsequently acquired by Sanofi S.A., from August 2001 to October 2011, culminating in Vice President, Finance. Mr. Becker received an M.B.A. from Babson College and a B.S. in Business Administration from the University of Massachusetts and was licensed as a certified public accountant.
|Total Annual Compensation, USD||405,682|
|Restricted Stock Award, USD||--|
|Long-Term Incentive Plans, USD||--|
|All Other, USD||2,044,850|
|Fiscal Year Total, USD||2,450,530|